Elefson, S. | bioRxiv Science

bioRxiv2026

Evaluation of a Novel Recombinant Human Protein Formula Compared to Donor Human Milk and Standard Formula in Neonatal Piglets

BackgroundDespite the advancements in infant nutrition, a gap still exists in the nutritional composition bioactive ingredients between infant formula and human milk. We developed a next-generation, proof-of-concept infant formula that contains recombinant human milk proteins. ObjectiveTo determine the impact of a novel infant formula (H1) on organ growth and development, and intestinal function compared to donor human milk (DHM) and standard infant formula (S) in a term piglet model. MethodsTerm piglets delivered via cesarean section were fed either a donor human milk (DHM) control, the investigational formula (H1), or infant formula (S) for 10 days. On d 10, a blood sample and tissues were collected. ResultsThere was no difference (P > 0.05) in piglet growth, although H1 piglets had a smaller relative stomach and liver than DHM and S piglets. H1 piglets had higher (P < 0.05) interleukins in the distal ileum, but no other systemic cytokines were elevated compared to the DHM and S piglets. H1 piglet small intestinal histology was similar (P > 0.05) to that of DHM and S piglets. Additionally, H1 piglets had either the same (P > 0.05) or higher (P < 0.05) amino acids in circulation compared to DHM and S piglets. Recombinant human proteins had either similar (P > 0.05) or lower (P < 0.05) activity compared to the native human proteins when assessing the individual ingredients in the H1 formula. ConclusionH1 formula was noninferior to DHM and S based on growth, small intestinal histology and plasma amino acid endpoints when fed to neonatal piglets. These findings warrant further studies to use the neonatal piglet as a model to evaluate more in-depth outcomes of health and safety for new infant formulas. Lay SummaryA novel piglet study shows a hypoallergenic, next-generation infant formula containing recombinant human milk proteins rivals donor human milk and standard formula for growth, gut health, and nutrient status.

physiology↗

bioRxiv2025

Pre- and postnatal 1,4-phenylene di-isothiocyanate treatment does not induce bile duct injury in neonatal pigs

BackgroundBiliary atresia (BA) is the leading cause of pediatric liver transplants, however; the cause of biliary atresia (BA) is unknown. Furthermore, the most common treatment for this disease is with a surgical procedure, which has a greater than 50% failure rate after 5 years. Due to a lack of proper animal models to study the pathology of the disease, little progress has been made in the field. ObjectiveThe objective of this study was to test whether pre and postnatal 1,4-phenylene di-isothiocyanate (DITC) would induce bile duct injury and cholestasis in neonatal pigs. MethodsPregnant sows received DITC once at gestation week 5 (100 mg/kg; n=2), or 3 times at gestation weeks 5, 6, and 7 (100 mg/kg each; n=2), or twice per week at gestation weeks 5-16 (15 mg/kg each; n=2). Cesarian-delivered piglets of the sows were randomly assigned to receive approximately 200 mg/kg DITC on days two, four, and six of life or to remain untreated. Piglets were fed enterally and collected blood samples were monitored for markers of liver injury for 14 days. At the end of 14 days, tissues were weighed and collected for immunohistochemistry and histopathology scoring. ResultsPiglets from sows that received DITC for 11 weeks had lower (P < 0.05) final body weight and daily gain compared to other treatments. Piglets from sows that received DITC for 11 weeks had a transient increase in gamma-glutamyl transferase. Liver histological scoring and analysis also did not show signs of BA. Piglets that received DITC from 11-week DITC-treated sows had elevated hepatic bile acids (P < 0.05), but there was no difference in serum bile acids (P > 0.05). ConclusionsThe administration of DITC to pregnant sows and neonatal piglets did not result in the development of bile duct or hepatic injury.

pathology↗